Uncommon but imperative cause of repeated acute stent thrombosis: Kounis syndrome type III

Shiro Miura,1 Takehiro Yamashita,1 Masaki Murata,2 Nicholas G Kounis3

SUMMARY
A 69-year-old woman with a history of allergic reactions to unknown metals who presented 1 year prior with acute coronary syndrome complicated by acute stent thrombosis (ST) was admitted due to new-onset chest pain during mild exercise. She electively underwent coronary angiography, revealing a newly developed stenosis in the fourth branch of the posterior descending artery, treated with an everolimus-eluting stent. One hour later, she reported of sudden chest tightness and nausea; ECG revealed significant ST-segment elevation in the II, III and aVF leads. We suspected ST-segment elevation myocardial infarction resulting from an allergic reaction (ie, Kounis syndrome type III) and managed it properly by eliminating other potential causes. The tentative diagnosis was confirmed by pathological examination of aspirated materials. Kounis syndrome type III may be a frequently undiagnosed clinical entity, emphasising the importance of pathological examination of aspirated materials when implanting coronary stents and history-taking of allergies to stent metals.

BACKGROUND
The Kounis syndrome was first reported in 1991 as an acute coronary syndrome, including coronary spasm (type I), atheromatous plaque erosion or rupture (type II) and stent thrombosis (ST) (type III), resulting from allergic or hypersensitivity reactions, or anaphylactic or anaphylactoid insults.1 In type III, all three components of drug-eluting stents (stent metals, polymers and eluted drugs) could be responsible for inducing allergic reactions and ST.2 To make an accurate diagnosis of Kounis syndrome type III, an urgent aspiration of intrastent thrombus, followed by histological examination of aspirated material and staining for eosinophils (H&E) and mast cells (Giemsa) can be mandatory.3 Concerning this point, Kounis syndrome type III may not be an uncommon disease but an infrequently misdiagnosed entity, which, however, has clinical significance because of the wide range of triggers and possible fatal consequences, unless promptly recognised. Herein, we report a novel case of repeated acute ST following a local allergic reaction diagnosis that was managed properly in a patient with a history of metal allergy.

DIFFERENTIAL DIAGNOSIS
ST-segment elevation myocardial infarction/acute stent thrombosis resulting from
► Procedure related (stent under-expansion, incomplete stent apposition and coronary artery dissection).
► Kounis syndrome (type III).
► Heparin-induced thrombocytopenia (HIT).
► Clopidogrel resistance.
► Plasma factors influencing the thrombophilic propensity (protein C, protein S, antithrombin III, activated protein C, antiphospholipid antibodies and anticardiolipin antibodies, etc).

TREATMENT
We suspected ST-segment elevation myocardial infarction resulting from an allergic reaction (ie, Kounis syndrome type III). Intravenous hydrocortisone (125 mg), oxygen and saline were immediately administered. Emergent CAG confirmed a further. Her medical history was noteworthy for acute coronary syndrome, 1 year before admission, complicated by acute ST in the proximal left anterior descending artery (LAD). This occurred 1 hour after the primary percutaneous coronary intervention (PCI) with a 2.5×26 mm zotarolimus-eluting stent (Resolute Onyx; Medtronic, Santa Rosa, California, USA) under the guidance of intravascular ultrasound (IVUS).

After admission, she electively underwent coronary angiography (CAG) on hospital day 2 to determine the cause of her chest pain. CAG revealed no in-stent restenosis in the proximal LAD (figure 1B) and critical stenosis in the fourth branch of the posterior descending artery (figure 1C). To treat the stenosis, which was thought to be the culprit lesion for her angina, a 2.25×38 mm everolimus-eluting stent (XIENCE Sierra; Abbott Vascular, Santa Clara, California, USA) was implanted (figure 2A,B) the same day. Aspirin (100 mg) and clopidogrel (75 mg) were administered daily as maintenance treatment 7 days prior to implantation. An IVUS (AltaView; Terumo Corporation, Tokyo, Japan) was performed to optimise the stenting by probing that no stent complications such as under-expansion, malposition or stent fracture were observed (figure 2C,D). One hour after the final angiogram, the patient reported of sudden chest tightness and nausea. There was no generalised itching or cutaneous erythema, and her vital signs were as follows: blood pressure, 173/86 mm Hg; heart rate, 76 beats/min and oxygen saturation, 98%. An ECG revealed significant ST-segment elevation in the II, III and aVF leads (figure 3).

CASE PRESENTATION
A 69-year-old woman with a medical history of hypertension was admitted to our heart centre with symptoms of chest pain during exercise. Mild allergic reactions to unknown metals were reported 30 years prior but had not been investigated.
thrombotic semi-occlusion of the stent site (figure 2E). Optical frequency domain imaging (OFDI) (LUNA WAVE, Terumo Corporation, Tokyo, Japan) revealed a residual thrombus overlying the stent struts (figure 2F,G). Aspiration thrombectomy and subsequent balloon angioplasty with a 3 mm non-compliant balloon were performed, which resulted in an improvement from thrombolysis in myocardial infarction (TIMI) flow grade 1–2 (figure 4A). The intra-aortic balloon was left in place for 3 days, during which time the TIMI flow grade in the right coronary artery was 3, as determined via CAG (figure 4B).

INVESTIGATIONS
After the bailout procedure, the peak troponin I and creatine kinase-MB levels were 27.8 pg/ml and 73.7 U/L, respectively. The lowest platelet count after thrombectomy and angiography was 180 x10⁹/L (initial platelet count, 195 x10⁹/L). The blood eosinophil percentage was 0.5% at 5 hours after the onset. As we suspected clopidogrel resistance, we replaced clopidogrel with prasugrel (20 mg as the loading dose, followed by 3.75 mg as the maintenance dose) during the bailout PCI.

Pathological examination of the thrombotic aspirate (figure 5A) revealed platelet aggregates, fibrin and white cells, including eosinophils and neutrophils (figure 5B); mast cells were not detected (figure 5C). CYP2C19*2 and CYP2C19*3 genotyping via polymerase chain reaction-restriction fragment length polymorphism analysis revealed that the patient was an intermediate metaboliser (CYP2C19 *1/*3 genotype). The activities of protein C, protein S, antithrombin III, activated protein C and α2-antiplasmin were within normal limits according to haematological tests. Antiphospholipid and anticardiolipin antibodies were negative. The above-mentioned findings were compatible with acute ST due to an allergic reaction. A patch test for metal allergies was strongly positive for nickel and cobalt, which are the main components of the patient’s two implanted coronary stents.

OUTCOME AND FOLLOW-UP
The patient’s clinical course was uneventful afterward, and she was discharged on hospital day 12 and had no symptoms at the 3-month follow-up visit.

DISCUSSION
Type III Kounis syndrome is defined as ST with eosinophils and mast cells in the aspirated thrombus. The lack of mast cells in our patient’s thrombotic material may have been due to the very short period between symptom onset and aspiration. In most previously reported cases with mast cells observed in implanted stent sites, histological analyses were performed several hours after the event or even during the autopsy. All components of drug-eluting coronary stents can potentially cause allergic reactions and Kounis syndrome type III along with possibly concomitant oral antiplatelet drugs and environmental exposures. Our patient had a positive allergic patch test response to nickel and
dyspnoea, and hypotension. Notably, her clinical course included focal hypersensitivity to the metals likely accounted for her apparent repeated acute ST.

The mechanisms underlying ST are multifactorial. Before concluding acute ST resulting from allergic reactions after the implantation of drug-eluting stents, we should explore other potential mechanisms, such as patient-related, procedural and postprocedural factors (including type and duration of anti-platelet therapy) as discussed previously. In our case, procedural factors, such as stent under-expansion, incomplete apposition and fracture, were unlikely to cause acute ST because the procedure was carefully performed via IVUS guidance and we also safely confirmed that these stent-related causes were much less likely via OFDI during the bailout PCI. HIT was a differential diagnosis if the patient administered heparin presented with thrombocytopenia or thrombosis. While the platelet count in this patient was within the normal limit and the relative change in platelets was not definitive to diagnose HIT, although the HIT test showed a weakly positive reaction. Similarly, plasma factors influencing the thrombophilic propensity, such as protein C, protein S, antithrombin III, activated protein C, antiphospholipid antibodies and anticardiolipin antibodies, were all within the normal range. Clopidogrel resistance is associated with subacute ST. We immediately switched 75 mg of clopidogrel to 3.75 mg of prasugrel, a third generation thienopyridine agent with greater platelet inhibition, and later, the patient disclosed not carrying CYP2C19 loss of-function alleles, which are seen more frequently in Japanese population. Overall, the abovementioned findings were compatible with acute repeated ST due to an allergic reaction.

To the best of our knowledge, this is the first report of repetitive acute ST induced by an allergic reaction, highlighting eosinophil infiltration in the aspirated thrombus on pathological examination. Using intradermal skin tests, we identified nickel and cobalt as the causes of the allergic reaction and consequent Kounis syndrome. Herein, this novel case conveys a significant message that Kounis syndrome type III should be considered when implanting coronary stents. Rather than being a rare disease, Kounis syndrome type III is a frequently undiagnosed clinical entity. Hence, we emphasise the importance of the pathological examination of aspirated materials and history-taking of previous allergic reactions to stent metals in cases of idiopathic ST.

Patient’s perspective

I am greatly engaged and interested in this clinical research of this especially unusual but important medical problem that I was suffering from. This novel report could hopefully contribute not only to improve my health condition in the future but also to deepen the understanding of the Kounis syndrome, leading to the further development of specific treatments for this clinical entity.

Learning points

- Kounis syndrome is an acute coronary syndrome caused by an allergic reaction to various drugs or substances.
- Kounis syndrome type III may be a frequently undiagnosed clinical entity when implanting coronary stents.
- Kounis syndrome type III warrants careful consideration, emphasising the importance of pathological examination of aspirated materials and history-taking of previous allergic reactions to stent metals.

REFERENCES
